The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Lopixibat chloride (Primary)
- Indications Alagille syndrome
- Focus Therapeutic Use
- Acronyms ITCH
- Sponsors Lumena Pharmaceuticals; Shire Pharmaceuticals
- 13 Jan 2017 Status changed from active, no longer recruiting to completed.
- 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.